Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
TMDX | US
-2.28
-2.01%
89377M109
89377M109
30/06/2024
24/04/2026
110.93
114.07
114.09
109.14
TransMedics Group Inc. a commercial-stage medical technology company engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS) a portable organ perfusion optimization and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage; and OCS Liver for the preservation of donor livers. The company was founded in 1998 and is headquartered in Andover Massachusetts.
View LessStrong Revenue Growth (> 10%)
Price Below SMA10D
High Short-term Volatility
Midcap (2B - 10B USD)
High Market Beta (> 0.8)
High Short percentage (> 15%)
High Debt to Equity (> 0.75)
High Debt to Asset (> 0.45)
Rich in Valuation (Price to Book > 8)
Weak Sharpe Ratio (< 0.3)
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
10 days
61.7%1 month
55.8%3 months
53.4%6 months
54.1%3.17K
92.59
22.31
2.72
0.68
144.90
12.24
-
42.81M
3.70B
3.70B
-
10.94
-
117.90
1.79
4.39
22.00
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
12.86
Range1M
27.83
Range3M
57.92
Rel. volume
0.92
Price X volume
87.71M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
No data | |||||||
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
No data | |||||||
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 144.90 | - | - |
| Ent. to Revenue | 12.24 | - | - |
| PE Ratio | 3,165.00 | - | - |
| Price to Book | 22.31 | - | - |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 53.39 | - | - |
| Debt to Equity | 2.72 | - | - |
| Debt to Assets | 0.68 | - | - |
| Market Cap | 3.70B | - | - |